{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Gainesville&page=62&state=Florida",
    "query": {
      "state": "Florida",
      "city": "Gainesville",
      "page": 62
    },
    "page_size": 10
  },
  "pagination": {
    "page": 62,
    "page_size": 10,
    "total_count": 5277,
    "total_pages": 528,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Gainesville&page=63&state=Florida&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Gainesville&page=61&state=Florida&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-09T22:29:35.413Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00506415",
      "title": "Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "Rivastigmine 5 cm^2",
          "type": "DRUG"
        },
        {
          "name": "Rivastigmine 10 cm^2",
          "type": "DRUG"
        },
        {
          "name": "Rivastigmine 15 cm^2",
          "type": "DRUG"
        },
        {
          "name": "Placebo to 15 cm^2 patch",
          "type": "DRUG"
        },
        {
          "name": "Placebo to 10 cm^2 patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 1584,
      "start_date": "2007-06",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2012-09-19",
      "last_synced_at": "2026-11-09T22:29:35.413Z",
      "location_count": 65,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 61 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00506415"
    },
    {
      "nct_id": "NCT05550532",
      "title": "A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Depressive Disorder, Major",
        "Anhedonia"
      ],
      "interventions": [
        {
          "name": "Aticaprant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 444,
      "start_date": "2022-12-06",
      "completion_date": "2024-11-13",
      "has_results": true,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-11-09T22:29:35.413Z",
      "location_count": 51,
      "location_summary": "Birmingham, Alabama • Lafayette, California • Orange, California + 40 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Lafayette",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Rancho Cucamonga",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05550532"
    },
    {
      "nct_id": "NCT03817398",
      "title": "Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Drug Withdrawn",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Tyrosine Kinase Inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "Up to 25 Years"
      },
      "enrollment_count": 110,
      "start_date": "2019-11-08",
      "completion_date": "2026-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-11-09T22:29:35.413Z",
      "location_count": 157,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 123 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03817398"
    },
    {
      "nct_id": "NCT05096221",
      "title": "A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "delandistrogene moxeparvovec",
          "type": "GENETIC"
        },
        {
          "name": "placebo",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Sarepta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "7 Years",
        "sex": "MALE",
        "summary": "4 Years to 7 Years · Male only"
      },
      "enrollment_count": 126,
      "start_date": "2021-10-27",
      "completion_date": "2024-10-25",
      "has_results": true,
      "last_update_posted_date": "2025-07-08",
      "last_synced_at": "2026-11-09T22:29:35.413Z",
      "location_count": 23,
      "location_summary": "Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 20 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05096221"
    },
    {
      "nct_id": "NCT07575399",
      "title": "Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Obesity or Overweight"
      ],
      "interventions": [
        {
          "name": "Maridebart Cafraglutide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 300,
      "start_date": "2026-05-11",
      "completion_date": "2028-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-11-06",
      "last_synced_at": "2026-11-09T22:29:35.413Z",
      "location_count": 56,
      "location_summary": "Pelham, Alabama • Chandler, Arizona • Sun City, Arizona + 48 more",
      "locations": [
        {
          "city": "Pelham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Sun City West",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07575399"
    },
    {
      "nct_id": "NCT02234843",
      "title": "EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "Up to 17 Years"
      },
      "enrollment_count": 500,
      "start_date": "2014-11-13",
      "completion_date": "2019-01-30",
      "has_results": true,
      "last_update_posted_date": "2020-04-01",
      "last_synced_at": "2026-11-09T22:29:35.413Z",
      "location_count": 23,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02234843"
    },
    {
      "nct_id": "NCT00419276",
      "title": "Effect of Ambulatory Continuous Femoral Nerve Blocks on Readiness-for-Discharge Following Total Knee Replacement",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Total Knee Arthroplasty"
      ],
      "interventions": [
        {
          "name": "Ambulatory continuous femoral nerve block for 100 hours",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 81,
      "start_date": "2007-04",
      "completion_date": "2010-08",
      "has_results": false,
      "last_update_posted_date": "2016-09-28",
      "last_synced_at": "2026-11-09T22:29:35.413Z",
      "location_count": 3,
      "location_summary": "Berkeley, California • San Diego, California • Gainesville, Florida",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00419276"
    },
    {
      "nct_id": "NCT00138671",
      "title": "A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus",
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Subcutaneous Insulin",
          "type": "DRUG"
        },
        {
          "name": "Inhaled Insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "77 Years",
        "sex": "ALL",
        "summary": "30 Years to 77 Years"
      },
      "enrollment_count": 105,
      "start_date": "2003-01",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2010-02-02",
      "last_synced_at": "2026-11-09T22:29:35.413Z",
      "location_count": 77,
      "location_summary": "Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 59 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00138671"
    },
    {
      "nct_id": "NCT02973087",
      "title": "rVWF IN PROPHYLAXIS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Von Willebrand Disease"
      ],
      "interventions": [
        {
          "name": "von Willebrand factor (Recombinant)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Antihemophilic Factor (Recombinant)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2017-11-16",
      "completion_date": "2020-07-06",
      "has_results": true,
      "last_update_posted_date": "2021-08-06",
      "last_synced_at": "2026-11-09T22:29:35.413Z",
      "location_count": 8,
      "location_summary": "Loveland, Colorado • Gainesville, Florida • Jacksonville, Florida + 5 more",
      "locations": [
        {
          "city": "Loveland",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Aurora",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02973087"
    },
    {
      "nct_id": "NCT02868021",
      "title": "Blood Flow Restriction Exercise Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Osteoarthritis, Knee"
      ],
      "interventions": [
        {
          "name": "Strength testing",
          "type": "DEVICE"
        },
        {
          "name": "Short Physical Performance Battery (SPPB)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Six-minute walk (SMW)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Numerical pain scale",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Self-assessed function",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Muscle biopsies",
          "type": "PROCEDURE"
        },
        {
          "name": "Determination of 1 Repetition Maximum (1-RM)",
          "type": "DEVICE"
        },
        {
          "name": "Blood flow restriction exercise",
          "type": "DEVICE"
        },
        {
          "name": "Borg CR10 scale",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "BEHAVIORAL",
        "PROCEDURE"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "55 Years to 80 Years"
      },
      "enrollment_count": 12,
      "start_date": "2016-12-12",
      "completion_date": "2018-08-01",
      "has_results": false,
      "last_update_posted_date": "2019-07-24",
      "last_synced_at": "2026-11-09T22:29:35.413Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02868021"
    }
  ]
}